Form 4: Mirum Pharmaceuticals Director Receives Equity Grant

Director Laurent Fischer was granted stock options and deferred stock units by Mirum Pharmaceuticals on June 15, 2026.

Summary

• Director Laurent Fischer received an equity grant consisting of 3,772 stock options and 1,980 deferred stock units.
• The stock options have an exercise price of $101 per share.
• Both the stock options and deferred stock units vest on the first anniversary of the grant date, or upon the date of the 2027 annual stockholder meeting, whichever occurs first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Market volatility could impact the value of the granted equity instruments.

Future Outlook

The equity grants are subject to vesting schedules tied to the 2027 annual stockholder meeting or the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and strategic alignment in the biotechnology sector.

Comparison to Industry Standards

• The use of deferred stock units and stock options is consistent with standard compensation packages for non-employee directors in mid-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders may experience minor dilution upon the exercise or settlement of these equity instruments.

Next Steps

• Vesting of equity grants on the first anniversary of the grant date or the 2027 annual stockholder meeting.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Trading, Equity Compensation, Director Compensation